Abiomed (NSDQ:ABMD) this week announced that the FDA has granted breakthrough device designation for its Impella ECP expandable percutaneous heart pump.
Danvers, Mass.-based Abiomed designed the Impella ECP heart pump to be compatible with small-bore access and closure techniques. It measures 3 mm in diameter when inserted and removed from the body. It expands in the heart to support the heart’s pumping function and provides a flow greater than 3.5 L/min.